Subscribe to RSS

DOI: 10.1055/s-0045-1811963
Elucidating the Role of TP53 in Oral Squamous Cell Carcinoma: A Cross-Sectional Observational Study of Integrated Analysis of Expression Patterns and Functional Importance
Authors
Funding None.

Abstract
Introduction
Oral squamous cell carcinoma (OSCC) is one of the major contributors of cancers associated with carcinoma, specifically among alcohol and tobacco consumers. Alterations in the TP53 gene are known to contribute to aggressive features of tumors. The present study explores miR-21, a microRNA targeting TP53 gene, focusing on the potential role of miR-21 in the regulation of OSCC pathogenesis at both computational and experimental levels.
Objective
This article aims to evaluate the expression and regulatory relationship between miR-21 and TP53 in OSCC, and to determine the potential of miR-21 as a therapeutic target.
Materials and Methods
This was a cross-sectional observational study designed to investigate the regulatory relationship between miR-21 and TP53 gene in OSCC. A total of 30 OSCC tissue samples and normal tissue samples were collected from patients undergoing surgical resection at Saveetha Dental College and Hospitals, following approval by the institutional ethics committee and after obtaining informed consent. Tissue specimens were immediately snap-frozen in liquid nitrogen and stored at −80 °C until further use.
The bioinformatics tools, TargetScan and miRDB, predicted the miRNAs that regulate TP53. The OSCC tissue samples were used to perform qRT-PCR following the extraction of RNA with TRIzol reagent for the expression profiling of miR-21 and TP53 gene.
Results
While TP53 gene expression was noticeably downregulated, the research showed that miR-21 was considerably increased in OSCC tissues. Given their inverse association, miR-21 may enhance carcinogenesis by suppressing TP53 activity.
Conclusion
The findings underscore the critical interplay between miR-21 and TP53 in OSCC pathogenesis. By regaining TP53 function, targeting miR-21 may offer a cutting-edge therapeutic approach for bettering patient outcomes. The clinical consequences of these interactions should be investigated further to provide tailored treatments for the management of OSCC.
Keywords
oral squamous cell carcinoma - microRNAs - gene expression - computational biology - biomarkerData Availability Statement
The datasets analyzed in this study are available from the corresponding author upon request.
Authors' Contributions
Conceptualization and formal analysis: D.S.; writing original draft: S.H.S.; data curation: A.K.P.; writing review and editing: D.S.
Patient's Consent
Informed consent was obtained from all the participants before conducting the interviews, and anonymity and confidentiality were ensured throughout the research process.
Publication History
Article published online:
23 September 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 R. Jr P., Yuwanati M, Sekaran S, M. S.. miRNA associated with glucose transporters in oral squamous cell carcinoma: a systematic review. Cureus 2023; 15 (09) e46057
- 2 Murugesan D, Kannan B, As SG, Jayaseelan VP, Arumugam P. Alteration of SERPINH1 is associated with elevated expression in head and neck squamous cell carcinomas and its clinicopathological significance. J Stomatol Oral Maxillofac Surg 2024; 125 (3S): 101811
- 3 Jayarajkumar S, Ramamoorthi R, Muniapillai S, Gopalakrishnan S, Jayaseelan VP. Assessment of salivary levels of ErbB2 in oral squamous cell carcinoma. J Oral Maxillofac Pathol 2023; 27 (04) 777-778
- 4 Veeraraghavan VP, Daniel S, Dasari AK, Aileni KR, Patil C, Patil SR. Emerging targeted therapies in oral oncology: focus on EGFR inhibition. Oral Oncol Rep 2024; 11: 100592
- 5 Shi Y, Ren X, Cao S. et al. TP53 gain-of-function mutation modulates the immunosuppressive microenvironment in non-HPV-associated oral squamous cell carcinoma. J Immunother Cancer 2023; 11 (08) e006666
- 6 Chen X, Zhang T, Su W. et al. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis 2022; 13 (11) 974
- 7 Noor H, Briggs NE, McDonald KL, Holst J, Vittorio O. TP53 mutation is a prognostic factor in lower grade glioma and may influence chemotherapy efficacy. Cancers (Basel) 2021; 13 (21) 5362
- 8 Nie D, Fu J, Chen H, Cheng J, Fu J. Roles of microRNA-34a in epithelial to mesenchymal transition, competing endogenous RNA sponging and its therapeutic potential. Int J Mol Sci 2019; 20 (04) 861
- 9 Zhang YY, Mao MH, Han ZX. Identification of a gene prognostic signature for oral squamous cell carcinoma by RNA sequencing and bioinformatics. BioMed Res Int 2021; 2021: 6657767
- 10 Shreya Reddy CS, Usman PPAS, Ganapathy DM, K.P A, Sekar D. MicroRNA-21 as a biomarker in terminal stage oral squamous cell carcinoma (OSCC) in the South Indian population. Oral Oncol Rep 2024; 9: 100139
- 11 Nautiyal M, Ganapathy D, KP A., Sekar D. Analysis of carboplatin and STAT3 in the breast cancer MCF7 cell line. Texila International Journal of Public Health 2024; 12 (02) 328-334
- 12 Kim K, Kim VN. High-throughput in vitro processing of human primary microRNA by the recombinant microprocessor. STAR Protoc 2022; 3 (01) 101042
- 13 Usman S, Jamal A, Teh MT, Waseem A. Major molecular signaling pathways in oral cancer associated with therapeutic resistance. Front Oral Health 2021; 1: 603160
- 14 Rajan C, Roshan VGD, Khan I. et al. MiRNA expression profiling and emergence of new prognostic signature for oral squamous cell carcinoma. Sci Rep 2021; 11 (01) 7298
- 15 Menon A, Abd-Aziz N, Khalid K, Poh CL, Naidu R. miRNA: a promising therapeutic target in cancer. Int J Mol Sci 2022; 23 (19) 11502
- 16 Ravi P, Babu S. Emerging immune checkpoint inhibitors for the treatment of oropharyngeal squamous cell carcinoma. Oral Oncol Rep 2024; 12: 100650